General Clinical Chemistry Analyzers and Accessories
DIASYS DIAGNOSTIC SYSTEMS USA LLC DIASYS LACTATE CHEM. REAGENT
NC3876872 DIASYS LACTATE CHEM. REAGENT
Anton Paar Litesizer DIA Series analyzes particle size and shape via direct imaging. Easily switch between liquid, air, or free-fall dispersion. Automated feed and rinsing simplify operation for fast, reliable measurements.
Specifications Litesizer DIA 700Measurement Principle: Dynamic Image AnalysisMeasurement Ranges (Liquid Flow): 0.5 μm to 2,500 μmMeasurement Ranges (Dry Jet): 0.5 μm to 5,000 μmMeasurement Ranges (Free Fall):0.5 μm to 16,000 μm (restrictions apply for particles >8,000 μm)Camera: 5 Mpix (2,448 pixels x 2,048 pixels) / 0.5 μm per pixelData Collection Rate 220 fps/camera at 5 MpixMagnification: 0.3x, 1x and 6xOptical Features: _Automatic switch between objectives_Automatic merge of size ranges_All magnifications are included in the standard configuration-_Data Transfer: 1x 10 Gigabit Ethernet, 1x USB-A 3.0Measurement Output_Number-, surface-, and volume-weighted results_Size descriptors (ISO 9276-compliant): Minimum and maximum Feret diameters, projected area equivalent diameter, length, geodesic length and thickness (e.g., for fibers), minimum and maximum axes of the Legendre ellipse_Shape descriptors (ISO 9276-compliant): aspect ratio, ellipse ratio, irregul
Abcam PF-04929113 (SN x -5422), 50MG
MW 521.5 Da, Purity >99%. Potent and selective Hsp90 inhibitor (IC₅₀ = 50 nM). A Her-2 degradation inducer (IC₅₀ = 37 nM).
The product is subject to the following: Abcam Restricted Use Statement
Abcam Vistusertib (AZD2014), 5MG
MW 462.5 Da, Purity >98%. Novel potent and selective mammalian rapamycin (mTOR) inhibitor (IC₅₀ = 2.8 nM). Highly selective against multiple PI3K isoforms. Also targets P-Akt (IC₅₀ = 80 nM) and pS6 (IC₅₀ = 200 nM). An oral inhibitor with potential anti-neoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LY2886721, BACE-1 inhibitor, 25MG
MW 390.4 Da, Purity >98%. Potent and selective BACE-1 inhibitor (IC₅₀ = 20.3 nM for recombinant hBACE-1). Human BACE2 is inhibited with an IC₅₀ of 10.2 nM. Does not inhibit other aspartyl proteases such as cathepsin D, pepsin, and renin. A potential agent to treat Alzheimer's Disease. Inhibits production of Aβ in HEK-293 Swe cells (IC₅₀ values are 18.5 nM and 19.7 nM for Aβ1-40 and Aβ1-42 respectively) and in PDAPP neuronal cells (IC₅₀ ~10 nM). Reduces dose-dependently brain levels of Aβ, C99 and sAPPβ in orally administered mouse model and plasma Aβ in dog model. Ppenetrates the blood-brain barrier.
The product is subject to the following: Abcam Restricted Use Statement
Abcam LGK974, 5MG
MW 396.4 Da, Purity >=98%. LGK-974 is a potent and specific inhibitor of Porcupine (porcn), a Wnt-specific acyltransferase (IC₅₀ = ~0.4 nM). GK974 potently inhibits Wnt signaling, has strong efficacy in rodent tumor models, and is well-tolerated. In addition, head and neck cancer cell lines with loss-of-function mutations in the Notch signaling pathway have a high response rate to LGK974.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Vistusertib (AZD2014), 10MG
MW 462.5 Da, Purity >98%. Novel potent and selective mammalian rapamycin (mTOR) inhibitor (IC₅₀ = 2.8 nM). Highly selective against multiple PI3K isoforms. Also targets P-Akt (IC₅₀ = 80 nM) and pS6 (IC₅₀ = 200 nM). An oral inhibitor with potential anti-neoplastic activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 50MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam ABT-199 (Venetocla x ), Bcl-2 inhibitor., 5MG
MW 868.4 Da, Purity >98%. Potent, selective Bcl-2 inhibitor (Ki <0.01 nM) that inhibits the growth of Bcl-2–dependent tumors while sparing platelets. Bcl-2–specific BH3 mimetic. Promising agent in the treatment of chronic lymphocytic leukaemic and estrogen receptor-positive breast cancer.
The product is subject to the following: Abcam Restricted Use Statement